Paion Ag logo

Paion Ag(FRA) PA8

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
N/A

Paion Ag Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 2, 2026

PA8 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Paion Ag

Paion AG is a specialized pharmaceutical company focused on developing and marketing innovative treatments in anesthesia, intensive care, and critical care medicine. The company emphasizes rapid-acting sedatives and other hospital-specific products, aiming to enhance patient care in critical settings.

Products and Services
  • Innovative anesthetics for surgical procedures
  • Rapid-acting sedatives for intensive care units
  • Specialized medications for critical care environments
Growth Outlook
  • Market demand for anesthesia products is steadily increasing
  • Expansion into new therapeutic areas is planned
  • Strategic partnerships may enhance product development
Financial Highlights
  • Revenue of €0.046 per share reflects market potential
  • Current ratio of 1.41 indicates strong liquidity position
  • Gross profit margin of 94.1% showcases operational efficiency
Paion AG operates in a niche market with significant growth potential, particularly in the fields of anesthesia and critical care. The company's focus on rapid-acting sedatives positions it well to meet the increasing demand for effective medical solutions. With a current ratio above 1, Paion AG demonstrates a solid liquidity position, which is crucial for funding ongoing research and development efforts. The impressive gross profit margin indicates that the company is effectively managing its costs while maximizing revenue potential. Overall, Paion AG presents an intriguing opportunity for investors interested in the pharmaceutical sector, particularly in innovative medical treatments.
AI Generated • Oct 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

70

CEO

Gregor Siebert

Website

paion.com

Headquarters

Aachen, NW 40213, DE

PA8 Financials

Key Financial Metrics (TTM)

Gross Margin

94.10%

Operating Margin

4.53%

Net Income Margin

-1.74%

Return on Equity

-8.51%

Return on Capital

N/A

Return on Assets

-1.52%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

€31.29M

Operating Income

€1.51M

EBITDA

€4.31M

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Paion Ag Performance Analysis

Paion Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31EUR 7,128,365N/A
20222022-12-31EUR 33,248,000366.4%
Paion Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31EUR -3.11N/A
20222022-12-31EUR -0.08-97.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACB.TOAurora Cannabis Inc.
CA$6.06-0.82%
CBGLCannabis Global Inc.
$0.00+0.00%
CURLFCuraleaf Holdings, Inc.
$8.68-1.59%
HCMHUTCHMED (China) Limited
$13.60+0.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$49.98-7.38%
CRWVCoreWeave
$66.28-14.82%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.88+9.25%
SOFISoFi Technologies
$14.23-6.66%

Questions About PA8

What is the current price of Paion Ag?

Paion Ag is trading at N/A per share.

What is the 52-week range for Paion Ag?

Over the past 52 weeks, Paion Ag has traded between N/A and N/A.

How much debt does Paion Ag have?

As of the most recent reporting period, Paion Ag reported total debt of €20.35M.

How much cash does Paion Ag have on hand?

Paion Ag reported €10.63M in cash and cash equivalents in its most recent financial results.

What is Paion Ag’s dividend yield?

Paion Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services